Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer
08 juin 2021 07h30 HE
|
Brooklyn ImmunoTherapeutics
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts
02 juin 2021 08h00 HE
|
Brooklyn ImmunoTherapeutics
BROOKLYN, N.Y., June 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...